Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Triple Negative Breast Neoplasms

Known as: Triple Negative Breast Neoplasms [Disease/Finding], ER Negative PR Negative HER2 Negative Breast Neoplasms, ER Negative PR Negative HER2 Negative Breast Cancer 
An invasive breast carcinoma which is negative for expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
BackgroundSeveral accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The… Expand
  • table 1
  • table 2
Review
2019
Review
2019
Importance Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Review
2019
Review
2019
Triple negative breast cancer (TNBC), which is typically lack of expression of estrogen receptor (ER), progesterone receptor (PR… Expand
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Review
2019
Review
2019
Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast cancer (TNBC) comprises around 15~20… Expand
Review
2019
Review
2019
Poly (ADP-ribose) polymerases (PARPs) play an important role in various cellular processes, such as replication, recombination… Expand
  • figure 1
  • figure 2
  • table 1
Review
2019
Review
2019
BACKGROUND Standard chemotherapy is associated with low response rates and short progression‐free survival among patients with… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • table 3
Review
2019
Review
2019
Triple negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation… Expand
Review
2019
Review
2019
BACKGROUND Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Review
2019
Review
2019
Cancer immunotherapy has evolved dramatically with improved understanding of immune microenvironment and immunosurveillance. The… Expand
  • figure 1
  • table 1
  • table 2
  • table 2
  • table 2
Review
2018
Review
2018
Abstract Breast cancer is the most prevalent cancer among women worldwide. Among the different breast cancer subtypes, triple… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
  • figure 2